Stockreport

NGM Bio Provides Pipeline Update and Reports Second Quarter 2019 Financial Results

NGM Biopharmaceuticals, Inc.  (NGM) 
Last ngm biopharmaceuticals, inc. earnings: 3/17 04:05 pm Check Earnings Report
PDF --Initiated Phase 1 clinical study of NGM621 for the treatment of dry age-related macular degeneration (AMD)-- --Completed enrollment of 1 mg cohort of 24-week Phase 2 [Read more]